Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUX-Lung 7
2011-001814-33Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) comparing Afatinib with Gefitinib (2 arms). Primary endpoints: Progression-free survival and Disease control rate at 12 months. Started Oct 2011; status: completed.
02
Drugs
afatinibgefitinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2011-001814-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001814-33.